Last reviewed · How we verify
CIPRO®XR
At a glance
| Generic name | CIPRO®XR |
|---|---|
| Also known as | CIPRO®XR tablets of Bayer Health Care |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Fasting Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg (PHASE1)
- Fasting Study of Ciprofloxacin Extended-Release Tablets 500 mg and Cipro® XR Tablets 500 mg (PHASE1)
- Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg (PHASE1)
- Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine (PHASE1)
- Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections (PHASE4)
- Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections (PHASE4)
- Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions (PHASE1)
- Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CIPRO®XR CI brief — competitive landscape report
- CIPRO®XR updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI